JP2021529780A5 - - Google Patents
Info
- Publication number
- JP2021529780A5 JP2021529780A5 JP2020573365A JP2020573365A JP2021529780A5 JP 2021529780 A5 JP2021529780 A5 JP 2021529780A5 JP 2020573365 A JP2020573365 A JP 2020573365A JP 2020573365 A JP2020573365 A JP 2020573365A JP 2021529780 A5 JP2021529780 A5 JP 2021529780A5
- Authority
- JP
- Japan
- Prior art keywords
- alkyl
- syndrome
- disease
- aryl
- autoimmune
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (9)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862693879P | 2018-07-03 | 2018-07-03 | |
| US201862693886P | 2018-07-03 | 2018-07-03 | |
| US62/693,879 | 2018-07-03 | ||
| US62/693,886 | 2018-07-03 | ||
| US201862702602P | 2018-07-24 | 2018-07-24 | |
| US201862702621P | 2018-07-24 | 2018-07-24 | |
| US62/702,621 | 2018-07-24 | ||
| US62/702,602 | 2018-07-24 | ||
| PCT/US2019/040357 WO2020010118A1 (en) | 2018-07-03 | 2019-07-02 | Methods of treating or selecting a treatment for a subject resistant to tnf inhibitor using a nlrp3 antagonist |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2021529780A JP2021529780A (ja) | 2021-11-04 |
| JP2021529780A5 true JP2021529780A5 (cg-RX-API-DMAC10.html) | 2022-07-11 |
Family
ID=67441657
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020573365A Pending JP2021529780A (ja) | 2018-07-03 | 2019-07-02 | Nlrp3アンタゴニストを使用するtnf阻害剤に対して抵抗性の対象のための治療の方法又は治療を選択する方法 |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US20220339169A1 (cg-RX-API-DMAC10.html) |
| EP (1) | EP3817737A1 (cg-RX-API-DMAC10.html) |
| JP (1) | JP2021529780A (cg-RX-API-DMAC10.html) |
| KR (1) | KR20210030947A (cg-RX-API-DMAC10.html) |
| CN (1) | CN112654350A (cg-RX-API-DMAC10.html) |
| AU (1) | AU2019299444A1 (cg-RX-API-DMAC10.html) |
| CA (1) | CA3103664A1 (cg-RX-API-DMAC10.html) |
| IL (1) | IL279889A (cg-RX-API-DMAC10.html) |
| WO (1) | WO2020010118A1 (cg-RX-API-DMAC10.html) |
Families Citing this family (33)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3649112A1 (en) | 2017-07-07 | 2020-05-13 | Inflazome Limited | Sulfonylureas and sulfonylthioureas as nlrp3 inhibitors |
| US11370763B2 (en) * | 2017-07-24 | 2022-06-28 | Novartis Ag | Compounds and compositions for treating conditions associated with NLRP activity |
| TW201910317A (zh) | 2017-08-15 | 2019-03-16 | 愛爾蘭商英弗雷佐姆有限公司 | 新穎化合物 |
| WO2019034693A1 (en) | 2017-08-15 | 2019-02-21 | Inflazome Limited | SULFONYLURATES AND SULFONYLTHIOURES AS INHIBITORS OF NLRP3 |
| MX2020001776A (es) | 2017-08-15 | 2020-03-24 | Inflazome Ltd | Sulfonilureas y sulfoniltioureas como inhibidores de nlrp3. |
| US11623922B2 (en) | 2017-10-03 | 2023-04-11 | Inflazome Limited | Compounds |
| WO2019092171A1 (en) | 2017-11-09 | 2019-05-16 | Inflazome Limited | Novel sulfonamide carboxamide compounds |
| CN111315733A (zh) | 2017-11-09 | 2020-06-19 | 英夫拉索姆有限公司 | 新颖磺酰胺甲酰胺化合物 |
| US11884645B2 (en) | 2018-03-02 | 2024-01-30 | Inflazome Limited | Sulfonyl acetamides as NLRP3 inhibitors |
| WO2019166632A1 (en) | 2018-03-02 | 2019-09-06 | Inflazome Limited | Novel compounds |
| US11834433B2 (en) | 2018-03-02 | 2023-12-05 | Inflazome Limited | Compounds |
| EP3759090A1 (en) | 2018-03-02 | 2021-01-06 | Inflazome Limited | Novel compounds |
| WO2019166619A1 (en) | 2018-03-02 | 2019-09-06 | Inflazome Limited | Novel compounds |
| MA53172A (fr) | 2018-07-20 | 2021-05-26 | Hoffmann La Roche | Composés de sulfonimidamide en tant qu'inhibiteurs de l'activité de l'interleukine 1 |
| MX2021000660A (es) | 2018-07-20 | 2021-03-25 | Hoffmann La Roche | Compuestos de sulfonilurea como inhibidores de la actividad de interleucina 1. |
| WO2021002887A1 (en) * | 2019-07-02 | 2021-01-07 | Novartis Inflammasome Research, Inc. | Gut-targeted nlrp3 antagonists and their use in therapy |
| CA3158123A1 (en) * | 2019-11-12 | 2021-05-20 | Yonggang Wei | Amide derivative and preparation method therefore and use thereof in medicine |
| BR112022014480A2 (pt) | 2020-01-22 | 2022-09-13 | Hoffmann La Roche | Compostos, composições farmacêutica, método para tratar um distúrbio em um paciente, usos de um composto e de uma composição farmacêutica e kit |
| CA3182276A1 (en) | 2020-05-08 | 2021-12-02 | Halia Therapeutics, Inc. | Inhibitors of nek7 kinase |
| WO2022047758A1 (en) * | 2020-09-05 | 2022-03-10 | Zhejiang University | Genetical disease modelling using mammals having nlrp3 mutation |
| CN117279903A (zh) * | 2021-02-10 | 2023-12-22 | 杭州英创医药科技有限公司 | 作为nlrp3抑制剂的化合物 |
| US11932630B2 (en) | 2021-04-16 | 2024-03-19 | Novartis Ag | Heteroaryl aminopropanol derivatives |
| CN116917282B (zh) * | 2021-05-10 | 2026-08-11 | 康百达(四川)生物医药科技有限公司 | 酰胺衍生物及其应用 |
| CN117693340A (zh) * | 2021-07-23 | 2024-03-12 | 诺华股份有限公司 | Nlrp3抑制剂治疗骨关节炎的给药方案 |
| EP4396349A4 (en) * | 2021-09-02 | 2025-10-22 | Molecular Axiom Llc | COMPOSITIONS AND METHODS FOR MODULATING NLRP3 OR NLRP1 EXPRESSION |
| WO2023098613A1 (zh) * | 2021-12-03 | 2023-06-08 | 南京明德新药研发有限公司 | 二甲基亚磺酰亚胺衍生物的制备方法 |
| US20230416412A1 (en) * | 2022-05-31 | 2023-12-28 | Hoffmann-La Roche Inc. | Prevention or mitigation of t-cell engaging agent-related adverse effects |
| CN119816304A (zh) * | 2022-07-27 | 2025-04-11 | 诺华股份有限公司 | Nlrp3抑制剂的给药方案 |
| CN116459260A (zh) | 2023-04-28 | 2023-07-21 | 中国人民解放军空军军医大学 | 一种特异性靶向nlrp3炎症小体抑制剂的用途 |
| WO2024248286A1 (ko) * | 2023-06-01 | 2024-12-05 | 한양대학교 에리카산학협력단 | 결핵균 유래 폴리펩타이드를 포함하는 암 치료용 약학 조성물 |
| WO2024248287A1 (ko) * | 2023-06-01 | 2024-12-05 | 한양대학교 에리카산학협력단 | 결핵균 유래 폴리펩타이드를 포함하는 염증성 질환 치료용 약학 조성물 |
| TW202513060A (zh) * | 2023-09-29 | 2025-04-01 | 瑞士商諾華公司 | 用於降低心血管疾病的風險之nlrp3抑制劑 |
| TW202545527A (zh) | 2024-01-16 | 2025-12-01 | 英商諾得瑟拉公司 | Nlrp3及glp-1a組合療法 |
Family Cites Families (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4987071A (en) | 1986-12-03 | 1991-01-22 | University Patents, Inc. | RNA ribozyme polymerases, dephosphorylases, restriction endoribonucleases and methods |
| US5116742A (en) | 1986-12-03 | 1992-05-26 | University Patents, Inc. | RNA ribozyme restriction endoribonucleases and methods |
| CA2065346C (en) | 1989-09-05 | 2005-03-29 | Craig A. Smith | Tumor necrosis factor-.alpha. and-.beta. receptors |
| CA2085297A1 (en) * | 1991-12-20 | 1993-06-21 | James Edward Ray | Sulfonimidamides |
| NZ256293A (en) | 1992-09-15 | 1997-06-24 | Immunex Corp | Method of treating tumour necrosis factor - mediated inflammation by use of tnf antagonist |
| US5705398A (en) | 1994-03-02 | 1998-01-06 | The Scripps Research Institute | Methods for identifying inhibitors of LPS-mediated LBP binding |
| US6090382A (en) | 1996-02-09 | 2000-07-18 | Basf Aktiengesellschaft | Human antibodies that bind human TNFα |
| ATE239041T1 (de) | 1996-02-09 | 2003-05-15 | Basf Ag | Humane antikörper welche an humanen tnfalpha binden |
| AU2002341321A1 (en) * | 2001-11-30 | 2003-06-10 | Pfizer Products Inc. | Combination of an il-1/18 inhibitor with a tnf inhibitor for the treatment of inflammation |
| SG146624A1 (en) * | 2003-09-11 | 2008-10-30 | Kemia Inc | Cytokine inhibitors |
| WO2006133286A2 (en) * | 2005-06-07 | 2006-12-14 | Tel Hashomer Medical Research Infrastructure And Services Ltd. | Treatment of tnf antagonist-resistant inflammatory disorders and related methods |
| US8884006B2 (en) | 2011-09-19 | 2014-11-11 | University Of Puerto Rico | Small-molecule inhibitors of Rac1 in metastatic breast cancer |
| US9714288B2 (en) | 2014-09-30 | 2017-07-25 | The Regents Of The University Of California | Antisense compounds and uses thereof |
| US20180008629A1 (en) * | 2015-01-29 | 2018-01-11 | Yale University | Compositions and Methods for Treating NLRP3 Inflammasome-Related Diseases and Disorders |
| JP6929792B2 (ja) * | 2015-02-16 | 2021-09-01 | ザ ユニバーシティ オブ クィーンズランド | スルホニル尿素及び関連化合物並びにその使用 |
| WO2017079352A2 (en) * | 2015-11-04 | 2017-05-11 | Idera Pharmaceuticals, Inc. | Compositions for inhibiting nlrp3 gene expression and uses thereof |
| WO2017123672A1 (en) * | 2016-01-12 | 2017-07-20 | Lawrence Chan | Combination treatment for inflammatory diseases |
| FR3046933B1 (fr) * | 2016-01-25 | 2018-03-02 | Galderma Research & Development | Inhibiteurs nlrp3 pour le traitement des pathologies cutanees inflammatoires |
| MA44729A (fr) | 2016-04-18 | 2021-05-12 | Novartis Ag | Composés et compositions pour traiter des états associés à une activité de nlrp |
| US11447460B2 (en) | 2016-04-18 | 2022-09-20 | Novartis Ag | Compounds and compositions for treating conditions associated with NLRP activity |
| CN110914256A (zh) * | 2017-07-07 | 2020-03-24 | 英夫拉索姆有限公司 | 新颖磺酰胺羧酰胺化合物 |
| US11370763B2 (en) * | 2017-07-24 | 2022-06-28 | Novartis Ag | Compounds and compositions for treating conditions associated with NLRP activity |
| JP7412328B2 (ja) * | 2017-07-24 | 2024-01-12 | ノバルティス アーゲー | Nlrp活性に関連する状態を治療するための化合物及び組成物 |
| US20200399242A1 (en) * | 2018-03-02 | 2020-12-24 | Inflazome Limited | Novel compounds |
-
2019
- 2019-07-02 JP JP2020573365A patent/JP2021529780A/ja active Pending
- 2019-07-02 CA CA3103664A patent/CA3103664A1/en not_active Abandoned
- 2019-07-02 US US17/252,630 patent/US20220339169A1/en not_active Abandoned
- 2019-07-02 WO PCT/US2019/040357 patent/WO2020010118A1/en not_active Ceased
- 2019-07-02 AU AU2019299444A patent/AU2019299444A1/en not_active Abandoned
- 2019-07-02 EP EP19745415.0A patent/EP3817737A1/en not_active Withdrawn
- 2019-07-02 CN CN201980052145.7A patent/CN112654350A/zh active Pending
- 2019-07-02 KR KR1020217003092A patent/KR20210030947A/ko not_active Withdrawn
-
2020
- 2020-12-30 IL IL279889A patent/IL279889A/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN116583508B (zh) | 一系列哌啶取代的苯酸类化合物及其应用 | |
| JP7551060B2 (ja) | プログラム可能なポリマー薬 | |
| JP7603918B2 (ja) | プログラム可能なポリマー薬 | |
| JP7618137B2 (ja) | プログラム可能なポリマー薬 | |
| CA3103664A1 (en) | Methods of treating or selecting a treatment for a subject resistant to tnf inhibitor using a nlrp3 antagonist | |
| US12486278B2 (en) | MASP-2 inhibitors and methods of use | |
| JP7721142B2 (ja) | Masp-2阻害剤および使用方法 | |
| JP2022505525A5 (cg-RX-API-DMAC10.html) | ||
| KR20250007056A (ko) | 악성 종양 치료용 제제 및 조성물 | |
| US12110288B2 (en) | MASP-2 inhibitors and methods of use | |
| AU2023266363A1 (en) | MASP-2 inhibitors and methods of use | |
| JP2019506380A5 (cg-RX-API-DMAC10.html) | ||
| AU2013227024A1 (en) | Novel piperidine compound or salt thereof | |
| RU2012144844A (ru) | Комплексные соединения железа(iii) для лечения и профилактики симптомов железодефицита и железодефицитной анемии | |
| JP7058322B2 (ja) | 細菌感染症を治療するための化合物および方法 | |
| JP2025521156A (ja) | Dnaポリメラーゼシータ阻害剤としてのチアジアゾリル誘導体およびその使用 | |
| JP2023509442A5 (cg-RX-API-DMAC10.html) | ||
| US20240336606A1 (en) | Substituted benzo or pyridopyrimidine amine inhibitor, preparation method therefor, and application thereof | |
| WO2024140923A1 (zh) | Prmt5-mta抑制剂 | |
| AU2018453128B2 (en) | Pan-KIT kinase inhibitor having quinoline structure and application thereof | |
| JP7731151B2 (ja) | トリアゾロピラジン系化合物及びその用途 | |
| US20250263383A1 (en) | Novel inhibitors of guanosine monophosphate synthetase as therapeutic agents | |
| WO2025166260A1 (en) | Amide substituted tricyclic guanidino compounds as prmt5 inhibitors | |
| WO2016050201A1 (zh) | 高选择性取代嘧啶类pi3k抑制剂 | |
| TWI627955B (zh) | β-咔啉生物鹼於抑制黃嘌呤氧化酶活性之用途 |